摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

oxiran-2-ylmethyl 4-[(butoxycarbonyl)amino]benzoate | 545357-96-8

中文名称
——
中文别名
——
英文名称
oxiran-2-ylmethyl 4-[(butoxycarbonyl)amino]benzoate
英文别名
Oxiran-2-ylmethyl 4-(butoxycarbonylamino)benzoate
oxiran-2-ylmethyl 4-[(butoxycarbonyl)amino]benzoate化学式
CAS
545357-96-8
化学式
C15H19NO5
mdl
——
分子量
293.32
InChiKey
ZXGQQYQASOKCQM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    391.2±17.0 °C(Predicted)
  • 密度:
    1.239±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    21
  • 可旋转键数:
    9
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    77.2
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    oxiran-2-ylmethyl 4-[(butoxycarbonyl)amino]benzoate盐酸 作用下, 以 乙醚乙醇 为溶剂, 反应 5.0h, 生成 (3-{4-[(butoxycarbonyl)amino]benzoyloxy}-2-hydroxypropyl)dimethylammonium chloride
    参考文献:
    名称:
    3-(二烷基氨基)-2-羟丙基4-[((烷氧基-羰基)氨基]苯甲酸酯和它们的季铵盐的合成,分析,抑制胆碱酯酶的活性和分子模型研究。
    摘要:
    合成了叔胺3-(二烷基氨基)-2-羟丙基4-[(烷氧羰基)氨基]苯甲酸酯及其季铵盐。季铵盐的合成的最后一步是通过微波辅助合成进行的。软件计算的数据提供了根据其理化性质比较十五种新化合物的背景。测定了叔胺的酸解离常数(pKa)和亲脂性指数(log P)。季铵盐通过软件计算的亲脂性指数和表面张力表征。生物学评估旨在测试合成化合物的乙酰胆碱酯酶和丁酰胆碱酯酶抑制活性。这些化合物可能的作用机理是通过结合对接技术的分子模型研究确定的。分子动力学模拟和量子力学计算。
    DOI:
    10.3390/molecules22122048
  • 作为产物:
    描述:
    氯甲酸丁酯吡啶氯化亚砜三乙胺 作用下, 以 四氢呋喃丙酮甲苯 为溶剂, 反应 7.5h, 生成 oxiran-2-ylmethyl 4-[(butoxycarbonyl)amino]benzoate
    参考文献:
    名称:
    3-(二烷基氨基)-2-羟丙基4-[((烷氧基-羰基)氨基]苯甲酸酯和它们的季铵盐的合成,分析,抑制胆碱酯酶的活性和分子模型研究。
    摘要:
    合成了叔胺3-(二烷基氨基)-2-羟丙基4-[(烷氧羰基)氨基]苯甲酸酯及其季铵盐。季铵盐的合成的最后一步是通过微波辅助合成进行的。软件计算的数据提供了根据其理化性质比较十五种新化合物的背景。测定了叔胺的酸解离常数(pKa)和亲脂性指数(log P)。季铵盐通过软件计算的亲脂性指数和表面张力表征。生物学评估旨在测试合成化合物的乙酰胆碱酯酶和丁酰胆碱酯酶抑制活性。这些化合物可能的作用机理是通过结合对接技术的分子模型研究确定的。分子动力学模拟和量子力学计算。
    DOI:
    10.3390/molecules22122048
点击查看最新优质反应信息

文献信息

  • Mokry; Zemanova; Csoellei, Pharmazie, 2003, vol. 58, # 1, p. 18 - 21
    作者:Mokry、Zemanova、Csoellei、Racanska、Tumova
    DOI:——
    日期:——
  • Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques
    作者:Ludmila E. Campos、Francisco M. Garibotto、Emilio Angelina、Jiri Kos、Tihomir Tomašič、Nace Zidar、Danijel Kikelj、Tomas Gonec、Pavlina Marvanova、Petr Mokry、Josef Jampilek、Sergio E. Alvarez、Ricardo D. Enriz
    DOI:10.1016/j.bioorg.2019.103125
    日期:2019.10
    The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of melanoma patients has driven the development of highly potent small inhibitors (BRAFi) of the mutated protein. To date, Dabrafenib and Vemurafenib, two specific BRAFi, have been clinically approved for the treatment of metastatic melanoma. Unfortunately, after the initial response, tumors become resistant and patients develop a progressive and lethal disease, making imperative the development of new therapeutic options. The main objective of this work was to find new BRAF inhibitors with different structural scaffolds than those of the known inhibitors. Our study was carried out in different stages; in the first step we performed a virtual screening that allowed us to identify potential new inhibitors. In the second step, we synthesized and tested the inhibitory activity of the novel compounds founded. Finally, we conducted a molecular modelling study that allowed us to understand interactions at the molecular level that stabilize the formation of the different molecular complexes.Our theoretical and experimental study allowed the identification of four new structural scaffolds, which could be used as starting structures for the design and development of new inhibitors of BRAF. Our experimental data indicate that the most active compounds reduced significantly ERK1/2 phosphorylation, a measure of BRAF inhibition, and cell viability. Thus, from our theoretical and experimental results, we propose new substituted hydroxynaphthalenecarboxamides, N-(hetero)aryl-piperazinylhydroxyalkylphenylcarbamates, substituted piperazinylethanols and substituted piperazinylpropandiols as initial structures for the development of new inhibitors for BRAF. Moreover, by performing QTAIM analysis, we are able to describe in detail the molecular interactions that stabilize the different Ligand-Receptor complexes. Such analysis indicates which portion of the different molecules must be changed in order to obtain an increase in the binding affinity of these new ligands.
  • An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors
    作者:Marcela Vettorazzi、Emilio Angelina、Santiago Lima、Tomas Gonec、Jan Otevrel、Pavlina Marvanova、Tereza Padrtova、Petr Mokry、Pavel Bobal、Lina M. Acosta、Alirio Palma、Justo Cobo、Janette Bobalova、Jozef Csollei、Ivan Malik、Sergio Alvarez、Sarah Spiegel、Josef Jampilek、Ricardo D. Enriz
    DOI:10.1016/j.ejmech.2017.08.017
    日期:2017.10
    Sphingosine kinase 1 (SphK1), the enzyme that produces the bioactive sphingolipid metabolite, sphingosine-1-phosphate, is a promising new molecular target for therapeutic intervention in cancer and inflammatory diseases. In view of its importance, the main objective of this work was to find new and more potent inhibitors for this enzyme possessing different structural scaffolds than those of the known inhibitors. Our theoretical and experimental study has allowed us to identify two new structural scaffolds (three new compounds), which could be used as starting structures for the design and then the development of new inhibitors of SphK1. Our study was carried out in different steps: virtual screening, synthesis, bioassays and molecular modelling. From our results, we propose a new dihydrobenzo[b] pyrimido[5,4-f]azepine and two alkyl3-/4-[-1-hydroxy-2-(4-arylpiperazin-1-yl)ethyliphenyl}carbamates as initial structures for the development of new inhibitors. In addition, our molecular modelling study using QTAIM calculations, allowed us to describe in detail the molecular interactions that stabilize the different Ligand-Receptor complexes. Such analyses indicate that the cationic head of the different compounds must be refined in order to obtain an increase in the binding affinity of these ligands. (C) 2017 Elsevier Masson SAS. All rights reserved.
  • Synthesis, Analysis, Cholinesterase-Inhibiting Activity and Molecular Modelling Studies of 3-(Dialkylamino)-2-hydroxypropyl 4-[(Alkoxy-carbonyl)amino]benzoates and Their Quaternary Ammonium Salts
    作者:Tereza Padrtova、Pavlina Marvanova、Klara Odehnalova、Renata Kubinova、Oscar Parravicini、Adriana Garro、Ricardo Enriz、Otakar Humpa、Michal Oravec、Petr Mokry
    DOI:10.3390/molecules22122048
    日期:——
    amines 3-(dialkylamino)-2-hydroxypropyl 4-[(alkoxycarbonyl)amino]benzoates and their quaternary ammonium salts were synthesized. The final step of synthesis of quaternary ammonium salts was carried out by microwave-assisted synthesis. Software-calculated data provided the background needed to compare fifteen new resulting compounds by their physicochemical properties. The acid dissociation constant (pKa)
    合成了叔胺3-(二烷基氨基)-2-羟丙基4-[(烷氧羰基)氨基]苯甲酸酯及其季铵盐。季铵盐的合成的最后一步是通过微波辅助合成进行的。软件计算的数据提供了根据其理化性质比较十五种新化合物的背景。测定了叔胺的酸解离常数(pKa)和亲脂性指数(log P)。季铵盐通过软件计算的亲脂性指数和表面张力表征。生物学评估旨在测试合成化合物的乙酰胆碱酯酶和丁酰胆碱酯酶抑制活性。这些化合物可能的作用机理是通过结合对接技术的分子模型研究确定的。分子动力学模拟和量子力学计算。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐